510TiP Camrelizumab combined with fruquintinib or regorafenib as second or later line therapy for BRAF positive-mutation advanced colorectal cancer (CRC) with microsatellite stability (MSS): A single-arm, phase II study

Abstract

CRC is an aggressive disease which accounts for a third of cancer-related death. Compared with the microsatellite instability-high phenotype, the effect of the BRAF mutation in the MSS-CRC on the prognosis seems to be more obvious. Regorafenib and furquintinib are small-molecule multikinase inhibitors that target signaling pathways implicated in tumor angiogenesis, oncogenesis and the tumor microenvironment. Camrelizumab, an anti-PD-1 monoclonal antibody, has shown preliminary results in advanced CRC.